Loading company…
Scripta Therapeutics uses AI and transcription factor research to develop drugs for neurodegenerative diseases.
Founded in 2025 and based in Oxford, UK, Scripta Therapeutics applies AI and machine learning to identify molecules that modulate transcription factors linked to Alzheimer’s, Parkinson’s and ALS. It works with pharmaceutical and biotechnology companies on drug discovery. In November 2025, it raised EUR 10.3 million in Seed funding from AlbionVC, Apollo Health Ventures, Oxford Sciences Enterprises, Parkwalk Advisors, and YZR.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in